Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial to evaluate the safety and tolerability of TQB3911 tablets in patients with BCR-ABL positive chronic myeloid leukemia, not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• TQB3911 (TQB3911)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Chronic Myelogenous Leukemia | Phase 1 | Status: NOT_YET_RECRUITING